Zota Health Care Past Earnings Performance
Past criteria checks 0/6
Zota Health Care's earnings have been declining at an average annual rate of -73.8%, while the Pharmaceuticals industry saw earnings growing at 13.4% annually. Revenues have been growing at an average rate of 17% per year.
Key information
-73.8%
Earnings growth rate
-73.2%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 17.0% |
| Return on equity | -21.4% |
| Net Margin | -15.8% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Getting In Cheap On Zota Health Care Limited (NSE:ZOTA) Might Be Difficult
Dec 04
Zota Health Care (NSE:ZOTA) Will Pay A Dividend Of ₹1.00
Sep 12Is Zota Health Care (NSE:ZOTA) A Risky Investment?
Aug 02Zota Health Care Limited's (NSE:ZOTA) 29% Jump Shows Its Popularity With Investors
Jun 15Zota Health Care (NSE:ZOTA) Has Re-Affirmed Its Dividend Of ₹1.00
Sep 20Zota Health Care (NSE:ZOTA) Has Announced A Dividend Of ₹1.00
Sep 04Are Dividend Investors Getting More Than They Bargained For With Zota Health Care Limited's (NSE:ZOTA) Dividend?
Mar 25What Type Of Returns Would Zota Health Care's(NSE:ZOTA) Shareholders Have Earned If They Purchased Their SharesYear Ago?
Jan 19
Zota Health Care Limited's (NSE:ZOTA) Has Been On A Rise But Financial Prospects Look Weak: Is The Stock Overpriced?
Dec 15Revenue & Expenses Breakdown
How Zota Health Care makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 2,201 | -347 | 629 | 0 |
| 30 Jun 24 | 1,981 | -242 | 421 | 0 |
| 31 Mar 24 | 1,805 | -143 | 372 | 0 |
| 31 Dec 23 | 1,685 | -101 | 312 | 0 |
| 30 Sep 23 | 1,565 | -104 | 263 | 0 |
| 30 Jun 23 | 1,494 | -78 | 148 | 0 |
| 31 Mar 23 | 1,408 | -58 | 213 | 0 |
| 31 Dec 22 | 1,345 | -41 | 168 | 0 |
| 30 Sep 22 | 1,306 | 24 | 165 | 0 |
| 30 Jun 22 | 1,269 | 47 | 104 | 0 |
| 31 Mar 22 | 1,313 | 89 | 159 | 0 |
| 31 Dec 21 | 1,308 | 92 | 224 | 0 |
| 30 Sep 21 | 1,303 | 48 | 221 | 0 |
| 30 Jun 21 | 1,231 | 26 | 222 | 0 |
| 31 Mar 21 | 1,072 | -2 | 216 | 0 |
| 31 Dec 20 | 993 | 12 | 136 | 0 |
| 30 Sep 20 | 939 | 26 | 139 | 0 |
| 30 Jun 20 | 910 | 27 | 100 | 0 |
| 31 Mar 20 | 952 | 27 | 145 | 0 |
| 31 Dec 19 | 926 | 32 | 137 | 0 |
| 31 Mar 19 | 856 | 55 | 123 | 0 |
| 31 Mar 18 | 779 | 73 | 81 | 0 |
| 31 Mar 17 | 716 | 55 | 85 | 0 |
| 31 Mar 16 | 647 | 51 | 69 | 0 |
| 31 Mar 15 | 565 | 43 | 54 | 0 |
| 31 Mar 14 | 501 | 31 | 42 | 0 |
Quality Earnings: ZOTA is currently unprofitable.
Growing Profit Margin: ZOTA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ZOTA is unprofitable, and losses have increased over the past 5 years at a rate of 73.8% per year.
Accelerating Growth: Unable to compare ZOTA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ZOTA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (20%).
Return on Equity
High ROE: ZOTA has a negative Return on Equity (-21.4%), as it is currently unprofitable.